3Settimana·

Altria Q4/FY2024 Earnings Review

Volume:

Combustables: -10%

Total Oral: -1%

On!: +40%

NJOY devices: +22%

NJOY consumables : +15%


Market Share:

Marlboro: 41.7% -60bps

Copenhagen: 19.1% -440bps

Skoal: 7.6% -170bps

On!: 8.3% +150bps

NJOY: 5.5% +280bps


NJOY ACE

In the patent dispute with JUUL, the ITC rules in favor of JUUL. As a result, the import and sale of NJOY ACE is banned and NJOY ACE will be off the market from April 2025.


Combustables Volume

There is no end in sight to the ever-shrinking US cigarette market.


Oral

Copenhagen (-8.8%) and Skoal (-9.9) are now shrinking at the same rate as the cigarette market; in my opinion, these can no longer be counted among the "new" alternative growth products as once planned by Altria. On! sales figures look good, but market share can only be gained very slowly.


Conclusion

On the whole, the report is quite sobering to disappointing. The goals that were set with NJOY have now been discarded and can no longer be achieved. And statements such as "we expect the Altria's future earnings growth to be negatively impacted by further "RRP catch-up investment"." are more than disappointing for me.

For me, this shows once again that the $MO (+1,86%) Altria management is no longer what it used to be. NJOY is finally on the market and they didn't manage to check the patent situation beforehand. Cronos, JUUL and now NJOY. One can only hope that they don't screw up with On!

2
9 Commenti

LOL :D No, Juul does not currently have full approval from the FDA in the US. In 2022, the FDA banned the sale of all Juul products because it determined that Juul had not adequately demonstrated that its products met health standards. However, this ban was later suspended while Juul appealed the decision, putting the company in legal limbo. The FDA lifted the ban in June 2024, but emphasized that this decision did not constitute approval of Juul's application and that the review was still ongoing. Thus, Juul does not currently have final approval, but is in a process in which the FDA is still reviewing its products.
1
immagine del profilo
3Settimana
Glad I sold !
The dividend will be missed, but I cashed in almost 20% in the green, all good to me
I find it very funny. When Altria still had big shares in Juul, Juul lost almost every lawsuit. As soon as Altria separated from Juul, Juul suddenly won almost every lawsuit. NJOY was right. No one could have guessed that the judges would now rule in Juul's favor. But I don't think the last word has been spoken yet. Altria is just no longer allowed to manufacture the parts in Asia. They just have to produce the parts themselves in the USA very quickly. But Juul doesn't produce its parts in China, does it?
My theory. Altria gives Juul 1 billion USD and Juul waives the lawsuit. Everyone could be happy with that, right?
NJOY has been around much longer than Juul but supposedly copied something? WTF? NJOY has been around since 2007. https://en.wikipedia.org/wiki/NJOY
Even if you have official FDA approval, that's not enough. You can still be sued to the hilt. You're never safe from lawsuits in the USA, are you?
In 2022, the FDA authorized several NJOY e-cigarette products to be legally marketed in the U.S.[15][16]
On April 27, 2022, the star product, NJOY Ace’s Premarket Tobacco Application (PMTA) was officially approved by the FDA, becoming the first closed system vape product loaded with ceramic coil pods to be authorized in the U.S. market. Moreover, NJOY became the first non-tobacco brand to be approved by the FDA.
Shouldn't Altria have stuck with Juul? That was called the biggest mistake of all time here for years. LOL :D
Partecipa alla conversazione